Verteporfin Suppresses the Proliferation, Epithelial-mesenchymal Transition and Stemness of Head and Neck Squamous Carcinoma Cells Via Inhibiting YAP1

Overview

Journal J Cancer

Specialty Oncology

Date 2019 Aug 16

PMID 31413738

Citations 15

Authors

Kui Liu

Shanmei Du

Peng Gao

Jie Zheng

Affiliations

Soon will be listed here.

Abstract

: Yes-associated protein 1 (YAP1) is overexpressed in head and neck squamous cell carcinoma (HNSCC). However, it is unknown whether verteporfin, a YAP1 inhibitor, can inhibit HNSCC cells as well as the molecular mechanisms involved. : YAP1 expression was investigated by immunohistochemistry in human head and neck carcinoma tissues (n=70). CCK-8 assay, colony formation assay, flow cytometric analysis, wound-healing assay and Transwell migration and invasion assays were used to evaluated the effects of verteporfin on the six HNSCC cell lines (three HPV-positive and three HPV-negative). The transcription and protein expression levels of and its associated genes were investigated by real-time PCR and Western blotting, respectively. The effects of verteporfin on HNSCC cells were assessed by a xenograft model. : YAP1 expression was significantly higher in carcinoma tissues than in tumor-adjacent normal tissues (n=10). A CCK-8 assay showed that the inhibitory effects of verteporfin on HNSCC cells were markedly enhanced by light activation. Verteporfin significantly inhibited HNSCC cell proliferation, migration and invasion, induced apoptosis, and arrested the cell cycle at the S/G2 phase. Verteporfin significantly attenuated the expression of genes related to epithelial-mesenchymal transition (, , and ) and stemness ( and ) and increased E-cadherin expression in HNSCC cells. Furthermore, verteporfin significantly inhibited PD-L1 expression in HNSCC cells. However, the expression levels of HPV-16 E6 and E7 did not change with VP treatment. The anticancer effect of verteporfin on HNSCC was confirmed by the inhibition of xenograft growth . : Our results indicate that YAP1 overexpression is involved in HNSCC tumorigenesis and verteporfin is a potential therapeutic drug for HNSCC.

Citing Articles

High-Performance Photodynamic Therapy of Tongue Squamous Cell Carcinoma with Multifunctional Nano-Verteporfin.

Yu L, Xu Z, Zhu G, Zeng L, Zhang Z, Yu Y Int J Nanomedicine. 2024; 19:2611-2623.

PMID: 38505166 PMC: 10949274. DOI: 10.2147/IJN.S452060.

Insights into the mechanisms and structure of breakage-fusion-bridge cycles in cervical cancer using long-read sequencing.

Rodriguez I, Rossi N, Keskus A, Xie Y, Ahmad T, Bryant A Am J Hum Genet. 2024; 111(3):544-561.

PMID: 38307027 PMC: 10940022. DOI: 10.1016/j.ajhg.2024.01.002.

Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases.

Talukdar P, Chatterji U Signal Transduct Target Ther. 2023; 8(1):427.

PMID: 37953273 PMC: 10641101. DOI: 10.1038/s41392-023-01651-w.

Nano-Photosensitizer Directed Targeted Phototherapy Effective Against Oral Cancer in Animal Model.

Yu L, Zhu G, Zhang Z, Xu Z, Peng W, Zeng L Int J Nanomedicine. 2023; 18:6185-6198.

PMID: 37933297 PMC: 10625746. DOI: 10.2147/IJN.S434917.

Alteration of Mesenchymal Stem Cells Isolated from Glioblastoma Multiforme under the Influence of Photodynamic Treatment.

Tumangelova-Yuzeir K, Minkin K, Angelov I, Ivanova-Todorova E, Kurteva E, Vasilev G Curr Issues Mol Biol. 2023; 45(3):2580-2596.

PMID: 36975539 PMC: 10047864. DOI: 10.3390/cimb45030169.

References

Granville D, Carthy C, Jiang H, LEVY J, McManus B, Matroule J . Nuclear factor-kappaB activation by the photochemotherapeutic agent verteporfin. Blood. 1999; 95(1):256-62. View

Belzacq A, Jacotot E, Vieira H, Mistro D, Granville D, Xie Z . Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target. Cancer Res. 2001; 61(4):1260-4. View

Hazan R, Qiao R, Keren R, Badano I, Suyama K . Cadherin switch in tumor progression. Ann N Y Acad Sci. 2004; 1014:155-63. DOI: 10.1196/annals.1294.016. View

Snijders A, Schmidt B, Fridlyand J, Dekker N, Pinkel D, Jordan R . Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene. 2005; 24(26):4232-42. DOI: 10.1038/sj.onc.1208601. View

Bentzen S, Atasoy B, Daley F, Dische S, Richman P, Saunders M . Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol. 2005; 23(24):5560-7. DOI: 10.1200/JCO.2005.06.411. View

DSouza G, Kreimer A, Viscidi R, Pawlita M, Fakhry C, Koch W . Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007; 356(19):1944-56. DOI: 10.1056/NEJMoa065497. View

Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I . Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis. 2008; 25(6):685-93. PMC: 2471394. DOI: 10.1007/s10585-007-9121-7. View

Chung C, Gillison M . Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009; 15(22):6758-62. DOI: 10.1158/1078-0432.CCR-09-0784. View

Ang K, Harris J, Wheeler R, Weber R, Rosenthal D, Nguyen-Tan P . Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010; 363(1):24-35. PMC: 2943767. DOI: 10.1056/NEJMoa0912217. View

10.

Leemans C, Braakhuis B, Brakenhoff R . The molecular biology of head and neck cancer. Nat Rev Cancer. 2010; 11(1):9-22. DOI: 10.1038/nrc2982. View

11.

Donohue E, Tovey A, Vogl A, Arns S, Sternberg E, Young R . Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J Biol Chem. 2011; 286(9):7290-300. PMC: 3044985. DOI: 10.1074/jbc.M110.139915. View

12.

Wang D, Su L, Huang D, Zhang H, Shin D, Chen Z . Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Mol Cancer. 2011; 10:116. PMC: 3192774. DOI: 10.1186/1476-4598-10-116. View

13.

Ge L, Smail M, Meng W, Shyr Y, Ye F, Fan K . Yes-associated protein expression in head and neck squamous cell carcinoma nodal metastasis. PLoS One. 2011; 6(11):e27529. PMC: 3212574. DOI: 10.1371/journal.pone.0027529. View

14.

Irvine K . Integration of intercellular signaling through the Hippo pathway. Semin Cell Dev Biol. 2012; 23(7):812-7. PMC: 3413921. DOI: 10.1016/j.semcdb.2012.04.006. View

15.

Cerami E, Gao J, Dogrusoz U, Gross B, Sumer S, Aksoy B . The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-4. PMC: 3956037. DOI: 10.1158/2159-8290.CD-12-0095. View

16.

Valenta T, Hausmann G, Basler K . The many faces and functions of β-catenin. EMBO J. 2012; 31(12):2714-36. PMC: 3380220. DOI: 10.1038/emboj.2012.150. View

17.

Hong W, Guan K . The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol. 2012; 23(7):785-93. PMC: 3459069. DOI: 10.1016/j.semcdb.2012.05.004. View

18.

Smith A, Teknos T, Pan Q . Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 2012; 49(4):287-92. PMC: 3586749. DOI: 10.1016/j.oraloncology.2012.10.009. View

19.

Arenz A, Ziemann F, Mayer C, Wittig A, Dreffke K, Preising S . Increased radiosensitivity of HPV-positive head and neck cancer cell lines due to cell cycle dysregulation and induction of apoptosis. Strahlenther Onkol. 2014; 190(9):839-46. DOI: 10.1007/s00066-014-0605-5. View

20.

Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller J . The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Exp Eye Res. 2014; 124:67-73. PMC: 4135181. DOI: 10.1016/j.exer.2014.04.011. View